Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia
暂无分享,去创建一个
M. Kesting | A. Agaimy | C. Wickenhauser | J. Jantsch | M. Büttner-Herold | J. Ries | F. Wehrhan | S. Frey | Manuel Weber | Christoph Baran | Stella Bolze | Eva Danzer | T. Möst
[1] M. Kesting,et al. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood. , 2020, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[2] R. Tishler,et al. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.
[3] P. Lequerica-Fernández,et al. Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression , 2020, Cancers.
[4] J. V. van Meerbeeck,et al. A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms , 2020, Frontiers in Oncology.
[5] J. Bagan,et al. Oral leukoplakia, a clinical-histopathological study in 412 patients , 2020, Journal of clinical and experimental dentistry.
[6] L. Fu,et al. PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake , 2020, Frontiers in Pharmacology.
[7] P. Ramos-García,et al. Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study. , 2020, Oral diseases.
[8] J. Zhao,et al. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. , 2020, Archives of oral biology.
[9] M. Kesting,et al. Malignant transformation of oral leukoplakia is associated with macrophage polarization , 2020, Journal of Translational Medicine.
[10] D. Baydar,et al. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy , 2020, World Journal of Urology.
[11] C. Thoma. PD-L1 and BCG response prediction , 2019, Nature Reviews Urology.
[12] R. Ferris,et al. Immunotherapy for head and neck cancer: Recent advances and future directions. , 2019, Oral oncology.
[13] M. He,et al. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. , 2019, Pathology, research and practice.
[14] M. Kesting,et al. Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile , 2019, Cancer medicine.
[15] O. Stasikowska-Kanicka,et al. CD8+ and CD163+ infiltrating cells and PD‐L1 immunoexpression in oral leukoplakia and oral carcinoma , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[16] Haitao Niu,et al. Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer , 2018, OncoTargets and therapy.
[17] R. Ferris,et al. Immunotherapy for Head and Neck Squamous Cell Carcinoma , 2018, Current Oncology Reports.
[18] J. Taube,et al. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.
[19] R. Pierce,et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. , 2017, Cancer research.
[20] A. Sharpe,et al. The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.
[21] F. Neukam,et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma , 2017, Oncotarget.
[22] T. Silva,et al. Overexpression of immunomodulatory mediators in oral precancerous lesions. , 2017, Human immunology.
[23] A. El‐Naggar,et al. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions , 2017, Cancer Prevention Research.
[24] Shaohua Chen,et al. Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[25] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[26] C. Rivera,et al. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review , 2017, bioRxiv.
[27] R. Greenslade. Interventions for treating oral leukoplakia to prevent oral cancer. , 2017, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[28] H. Kumamoto,et al. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. , 2017, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[29] C. Obayashi,et al. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. , 2017, Oral oncology.
[30] H. Zeng,et al. Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma , 2016, Mediators of inflammation.
[31] C. Jiang,et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] K. Amann,et al. Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas—an immunohistochemical study , 2015, British Journal of Cancer.
[33] F. Neukam,et al. Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages--an immunohistochemical analysis. , 2014, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.
[34] F. Neukam,et al. Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes – an immunohistochemical study , 2014, BMC Cancer.
[35] Lieping Chen,et al. PD-1 as an immune modulatory receptor. , 2014, Cancer journal.
[36] Matthew N. McCall,et al. On non-detects in qPCR data , 2014, Bioinform..
[37] Deepak Mittal,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[38] S. Cheong,et al. Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory , 2014, International journal of cancer.
[39] T. Yen,et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer , 2012, Clinical chemistry and laboratory medicine.
[40] E. Nkenke,et al. Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. , 2012, International journal of oncology.
[41] E. Nkenke,et al. Detection of MAGE-A Expression Predicts Malignant Transformation of Oral Leukoplakia , 2012, Cancer investigation.
[42] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[43] A. Ribeiro-Silva,et al. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. , 2011, International journal of oral and maxillofacial surgery.
[44] G. Pitiyage,et al. Molecular markers in oral epithelial dysplasia: review. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[45] J. Bouquot,et al. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. , 2008, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[46] T. Axéll,et al. Management of oral epithelial dysplasia: a review. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[47] B. Zetter,et al. Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.
[48] J. Sudbø,et al. Which putatively pre-malignant oral lesions become oral cancers? Clinical relevance of early targeting of high-risk individuals. , 2003, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[49] P. Reichart,et al. [Oral leukoplakia in manifest squamous epithelial carcinoma. A clinical prospective study of 101 patients]. , 1998, Mund-, Kiefer- und Gesichtschirurgie : MKG.
[50] J. Grandis,et al. WHO classification of head and neck tumours , 2017 .
[51] J. Reibel. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[52] K. Riden,et al. CLASSIFICATION OF HEAD AND NECK TUMOURS , 1998 .
[53] G. Plewig,et al. Dermatologie und Venerologie , 1969 .